Sweden has reached the UNAIDS and WHO targets for the HIV epidemic, according to a study in Eurosurveillance by researchers ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

A Rutgers Health study suggests telehealth could be a viable long-term option for people living with HIV, potentially saving ...

The national HIV prevalence was 16. 3% among adults aged 15 years and older, translating to an estimated 7. 4 million adults ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...

Here Ncube shares her thoughts on HIV cure vs prevention ... In the recently conducted PURPOSE 1 and PURPOSE 2 trials, the drug demonstrated remarkable efficacy in preventing HIV acquisition.

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Sweden has reached the UNAIDS and WHO targets for the HIV epidemic, according to a study in Eurosurveillance by researchers ...

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...